Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its ...
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated ...
MedPage Today on MSN
Double-Action Lupus Drug Looks Good in Phase III Trial
A novel drug for systemic lupus erythematosus (SLE) first developed in China, and approved there since 2021, did well enough in a new placebo-controlled phase III trial that approval in Western ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study ...
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 16, 2025 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a ...
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today ...
Ahead of the 2025 European AIDS Conference in Paris, researchers discovered a new antibody against HIV. They say it can ...
The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...
Bristol Myers Squibb's acquisition of Orbital Therapeutics includes OTX-201, a next-gen CAR T-cell therapy, and a proprietary ...
Researchers have developed a nanoparticle vaccine that prevented melanoma, pancreatic and triple-negative breast cancer in ...
Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand ...
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback